CN Patent

CN107267481A — Cdk5抗原表位肽及其应用

Assigned to XinHua Hospital Affiliated To Shanghai JiaoTong University School of Medicine · Expires 2017-10-20 · 9y expired

What this patent protects

本发明公开了一种抗原表位肽，其氨基酸序列含有SEQ ID No.2或SEQ ID No.3所示的氨基酸序列，或含有对SEQ ID No.2或SEQ ID No.3所示的氨基酸序列添加、缺失或替换一个或多个氨基酸形成的氨基酸序列。该抗原表位肽可以用于产生抗原呈递细胞、主要组织相容性抗原复合物或细胞毒性T淋巴细胞诱导剂，还能应用于制备治疗如胶质瘤的癌症的药物中。

USPTO Abstract

本发明公开了一种抗原表位肽，其氨基酸序列含有SEQ ID No.2或SEQ ID No.3所示的氨基酸序列，或含有对SEQ ID No.2或SEQ ID No.3所示的氨基酸序列添加、缺失或替换一个或多个氨基酸形成的氨基酸序列。该抗原表位肽可以用于产生抗原呈递细胞、主要组织相容性抗原复合物或细胞毒性T淋巴细胞诱导剂，还能应用于制备治疗如胶质瘤的癌症的药物中。

Drugs covered by this patent

ribociclib-succinate (RIBOCICLIB SUCCINATE)

Patent Metadata

Patent number: CN107267481A
Jurisdiction: CN
Classification: —
Expires: 2017-10-20
Drug substance claim: No
Drug product claim: No
Assignee: XinHua Hospital Affiliated To Shanghai JiaoTong University School of Medicine
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.